Home » Entries posted by Hellenic Atherosclerosis Society (Page 3)
Volume 7 | Supplement 1 | December 2016

Volume 7 | Supplement 1 | December 2016

Hellenic Journal of Atherosclerosis Volume 7 | Supplement 1 | December 2016 Abstracts 7th Congress of the Hellenic Atherosclerosis Society Read full text here

What is Familial Hypercholesterolemia?

What is Familial Hypercholesterolemia?

    Familial Hypercholesterolemia is a common inherited disease. It affects almost 1 in 250 persons. People with FH are born with dangerously high levels of cholesterol. See the FH Infographic        

Pathophysiological mechanisms of dyslipidemia in patients with nephrotic syndrome: A fresh look

Pathophysiological mechanisms of dyslipidemia in patients with nephrotic syndrome: A fresh look

HELLENIC JOURNAL OF ATHEROSCLEROSIS | VOLUME 7 – ISSUE 3 (JULY– SEPTEMBER 2016) Review Pathophysiological mechanisms of dyslipidemia in patients with nephrotic syndrome: A fresh look S. Filippas-Ntekouan, M.S. Elisaf (102 – 110) Key words: nephrotic syndrome; dyslipidemia; PCSK9; increased LDL CHOL levels

Is there a need for other cardiovascular risk factors besides the established risk factors?

Is there a need for other cardiovascular risk factors besides the established risk factors?

HELLENIC JOURNAL OF ATHEROSCLEROSIS | VOLUME 7 – ISSUE 3 (JULY– SEPTEMBER 2016) Editorial Is there a need for other cardiovascular risk factors besides the established risk factors? K. Tziomalos

PCSK9 Inhibitors: Research and new perspectives in clinical practice

PCSK9 Inhibitors: Research and new perspectives in clinical practice

HELLENIC JOURNAL OF ATHEROSCLEROSIS | VOLUME 7 – ISSUE 3 (JULY– SEPTEMBER 2016) Review PCSK9 Inhibitors: Research and new perspectives in clinical practice E. Charatsi, I. Tsigeridis

Familial hypercholesterolemia is undertreated in clinical practice

Familial hypercholesterolemia is undertreated in clinical practice

HELLENIC JOURNAL OF ATHEROSCLEROSIS | VOLUME 7 – ISSUE 3 (JULY– SEPTEMBER 2016) Original Article Familial hypercholesterolemia is undertreated in clinical practice F. Barkas, E. Liberopoulos, G. Liamis, M. Elisaf

HELLENIC JOURNAL OF ATHEROSCLEROSIS | VOLUME 7 – ISSUE 3 (JULY– SEPTEMBER 2016)

HELLENIC JOURNAL OF ATHEROSCLEROSIS | VOLUME 7 – ISSUE 3 (JULY– SEPTEMBER 2016)

  CONTENTS Editorial Is there a need for other cardiovascular risk factors besides the established risk factors? K. Tziomalos (97 – 101) Reviews Pathophysiological mechanisms of dyslipidemia in patients with nephrotic syndrome: A fresh look S. Filippas-Ntekouan, M.S. Elisaf (102 – 110) PCSK9 Inhibitors: Research and new perspectives in clinical practice E. Charatsi, I. Tsigeridis […]

A patient with a recent acute coronary syndrome. Which is the optimal antiplatelet regimen?

A patient with a recent acute coronary syndrome. Which is the optimal antiplatelet regimen? Lecture: R. Durst (Israel)  

LDL-cholesterol. How low should we go and with which agent(s)?

LDL-cholesterol. How low should we go and with which agent(s)? Lecture: D. P. Mikhailidis (UK) 9th Summer School of the Hellenic Atherosclerosis Society

Azilsartan, a promising Angiotensin II Receptor Blocker in the management of hypertension

Azilsartan, a promising Angiotensin II Receptor Blocker in the management of hypertension

HELLENIC JOURNAL OF ATHEROSCLEROSIS | VOLUME 7 – ISSUE 2 (APRIL– JUNE 2016) Review Azilsartan, a promising Angiotensin II Receptor Blocker in the management of hypertension C. Antza, I. Doundoulakis, S. Stabouli, V. Kotsis (53 – 62) Key words: azilsartan; arb; raas ; hypertension